. 2023 Dec 1;102(48):e36391. doi: 10.1097/MD.0000000000036391

Table 2.

Characteristics of the included studies.

Author/yr of publication	Study design	No. patients/sockets	Male/female	Age (yr)	Grafted sites (number)	Grafted materials	No. implants	Reentry (mo)	Follow-up (mo)
Group I: APD versus BCH
del Canto-Díaz et al 2019	Split-mouth RCT	6/12	3/3	47.6 ± 9.04	NR	APD: Filled with 300–1200 µm mineralized APD, covering 15*20 mm collagen membrane			2, 4
del Canto-Díaz et al 2019	Split-mouth RCT	6/12	3/3	47.6 ± 9.04	NR	BCH: Covered 15*20 mm collagen membrane			2, 4
Isola et al 2022	Split-mouth RCT	14/28	6/8	48.2 (37–62)	Maxillary anterior region	APD: Filled with mineralized APD, covering free gingival graft	APD: 14	4	19
Isola et al 2022	Split-mouth RCT	14/28	6/8	48.2 (37–62)	Maxillary anterior region	BCH: Covered free gingival graft	BCH: 14	4	19
Joshi et al 2016	Split-mouth RCT	15/45	9/6	35.6 ± 5.7 (28–45)	APD: Upper (10), lower (5)	APD: Filled with 300–500 µm partially demineralized APD, covering chorion membrane (Tissue Bank, India)			4
					OGM: Upper (8), lower (7)	OGM: Filled with β-TCP alloplast (SyboGraf-T Plug, India), covering chorion membrane (Tissue Bank, India)
					BCH: Upper (8), lower (7)	BCH: Covered chorion membrane (Tissue Bank, India)
Kuperschlag et al 2020	Split-mouth RCT	13/24 (APD: 13 sites; BCH: 11 sites)	3/10	22.61 (18–27)	Third molar	APD: Filled with demineralized APD, absorbable hemostatic gelatin sponge			3, 12
Kuperschlag et al 2020	Split-mouth RCT	13/24 (APD: 13 sites; BCH: 11 sites)	3/10	22.61 (18–27)	Third molar	BCH: Absorbable hemostatic gelatin sponge			3, 12
Mazzucchi et al 2022	Split-mouth RCT	10/20	4/6	32.7 ± 9.8	Third molar	APD: Filled with 300–1200 µm demineralized APD			3, 6
Mazzucchi et al 2022	Split-mouth RCT	10/20	4/6	32.7 ± 9.8	Third molar	BCH: No graft			3, 6
Sánchez-Labrador et al 2020	Split-mouth RCT	15/30	4/11	21.86	Third molar	APD: Filled with 300–1200 µm demineralized APD, fibrin sponge (Gelatamp, Germany)		m	3, 6
Sánchez-Labrador et al 2020	Split-mouth RCT	15/30	4/11	21.86	Third molar	BCH: No graft		m	3, 6
Yüceer-Cetiner et al 2021	RCT	APD: 3/20	4/5	31–62	NR	APD: Filled with 300–1200 µm demineralized APD, covering resorbable membrane (Bio-Gide, Geistlich, Switzerland)	NR	3
Yüceer-Cetiner et al 2021	RCT	BCH: 3/16	4/5	31–62	NR	BCH: No graft	NR	3
Group II: APD versus OGM
Jung et al 2018	RCT	APD: 8/8	APD: 4/4	APD: 46.63 ± 18.12	APD: Molar (7)	APD: Filled with demineralized APD, covering absorbable atelocollagen plug (Rapiplug, Korea)	NR		4
Jung et al 2018	RCT	OGM: 8/8	OGM: 5/3	OGM: 49.75 ± 17.21	OGM: Premolar (3), molar (5)	OGM: Filled with Bio-Oss Collagen, covering absorbable atelocollagen plug (Rapiplug, Korea)	NR		4
Pang et al 2017	RCT	APD: 15/21	APD: 8/7	APD: 58.53 ± 7.66	APD: Maxilla (14), mandible (7)	APD: Filled with 300–800 µm demineralized APD	APD: 15	6
Pang et al 2017	RCT	OGM: 9/12	OGM: 3/6	OGM: 60.56 ± 10.49	OGM: Maxilla (7), mandible (5)	OGM: Filled with Bio-Oss (Geistlich, Switzerland)	OGM: 9	6
Santos et al 2021	RCT	APD: 26/34	APD: 15/11	APD: 56.8 ± 12.3	APD: Anterior (12), posterior (22)	APD: Filled with 250–1200 µm mineralized APD, covering resorbable barrier membrane (Bio-Gide, Geistlich, Switzerland) and free gingival graft	APD: 34	6	12, 18
Santos et al 2021	RCT	OGM: 26/32	OGM: 16/10	OGM: 61.5 ± 13.1	OGM: Anterior (19), posterior (13)	OGM: Filled with Bio-Oss, covering resorbable barrier membrane (Bio-Gide, Geistlich, Switzerland) and free gingival graft	OGM: 32	6	12, 18
Author/yr of publication	Primary outcomes							Secondary outcomes
Author/yr of publication	Change in horizontal ridge width (mm)		Change in labial bone height (mm)		Histomorphometry (%)			Primary implant stability	Postoperative complications
Group I: APD versus BCH
del Canto-Díaz et al 2019	APD: 2 mo: −0.17 ± 0.55; 4 mo: −0.46 ± 0.56		APD: 2 mo: −0.14 ± 0.75; 4 mo: −0.16 ± 0.78						NR
del Canto-Díaz et al 2019	BCH: 2 mo: −1.11 ± 0.98; 4 mo: −1.91 ± 1.43		BCH: 2 mo: −0.29 ± 2.24; 4 mo: −2.22 ± 2.07
Isola et al 2022					APD: Vital bone: 34.23 ± 13.56; residual grafts: 30.22 ± 14.48; connective tissue: 27.36 ± 9.65			NR	0
Isola et al 2022					BCH: Vital bone: 30.22 ± 14.48; connective tissue: 29.23 ± 10.16
Joshi et al 2016	APD: −0.15 ± 0.08		APD: −0.28 ± 0.13						0
	OGM: −1.45 ± 0.40		OGM: −1.72 ± 0.56
	BCH: −2.29 ± 0.40		BCH: −2.60 ± 0.88
Kuperschlag et al 2020									0
Mazzucchi et al 2022									0
Sánchez-Labrador et al 2020									APD: 2 (1 abscess, 1 wound dehiscence)
Sánchez-Labrador et al 2020									3 (1 abscess, 1 wound dehiscence, 1 hematoma)
Yüceer-Cetiner et al 2021					APD: Vital bone: 19.32 ± 1.91; vessel: 14.76 ± 0.94; connective tissue: 41.57 ± 3.63				0
Yüceer-Cetiner et al 2021					BCH: Vital bone: 18.68 ± 1.18; vessel: 16.92 ± 0.66; connective tissue: 27.34 ± 2.06
Group II: APD versus OGM
Jung et al 2018	APD: −0.78 ± 0.41				APD: Vital bone: 32.88 ± 14.48; residual grafts: 10.72 ± 9.83; connective tissue:56.40 ± 8.58				APD: 2 (pain)
Jung et al 2018	OGM: −1.68 ± 1.11				OGM: Vital bone: 22.00 ± 11.01; residual grafts: 13.20 ± 9.79; connective tissue:64.80 ± 10.11				OGM: 1 (swelling and pain)
Pang et al 2017					APD: Vital bone: 31.24 ± 13.87; residual grafts: 8.95 ± 6.15; connective tissue:59.81 ± 15.50			APD: 72.80 ± 10.81	0
Pang et al 2017					OGM: Vital bone: 35.00 ± 19.33; residual grafts: 17.08 ± 16.57; connective tissue:47.93 ± 24.46			OGM: 70.0 ± 12.86	0
Santos et al 2021					APD: Vital bone: 47.3 ± 14.8; residual grafts: 12.2 ± 7.7; connective tissue:40.5 ± 17.6			APD: 77.1 ± 6.9	0
Santos et al 2021					OGM: Vital bone: 34.9 ± 13.2; residual grafts: 22.1 ± 10.9; connective tissue:42.9 ± 9.6			OGM: 77.0 ± 5.9	0

β-TCP = beta-tricalcium phosphate, APD = autogenous particulated dentin group, BCH = blood clot healing group, NR = not report, OGM = other grafted materials group, RCT = randomized controlled trial.